This site is intended for Healthcare Professionals outside the US

MF
PV
  1. About PV
  2. Elevated Haematocrit

Inability to achieve and consistently maintain haematocrit <45% can have serious consequences

Even moderate increases in haematocrit levels (45%-50%) were associated with significant increases in risk of major events1

Increased risks with elevated haematocrit despite phlebotomy and/or cytoreductive therapy1

PV patients with elevated haematocrit level despite phlebotomy and/or cytoreductive therapy have increased risk of cardiovascular and/or haematocrit events - JAKAVI

Elevated risk was observed in the high haematocrit group (median haematocrit of 47.5%) compared with the low haematocrit group (median of 44.4%)1

  • Supplemental phlebotomy may not consistently maintain target haematocrit levels2

Learn about haematocrit control with JAKAVI

Next: Leukocytosis is associated with thrombotic risk

CV=cardiovascular; HCT=haematocrit.

References:

  1. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
  2. Verstovsek S, Kiladjian J-J, Mesa R, et al. Ruxolitinib efficacy by hematocrit control in patients with polycythemia vera: an analysis of the RESPONSE trial. Blood. 2014;124(21):3201.